The case for the health system specialty pharmacy coordinated care model


Kristin Chambers, Vice President of Strategic Development, Integrated Health Systems Outcomes Coalition, shares the important benefits of clinical coordination, access opportunities/challenges and how health systems can build meaningful relationships with manufacturers.

Year after year, the specialty pharmaceutical product category continues to grow and become more integral to patient care.

In fact, nearly 50 percent of all drugs will be in the specialty category by 20221. Payers reported that specialty drugs accounted for 32 percent of pharmacy costs2 and 22 percent of medical benefit costs3 in 2016. At the forefront of this trend are health system specialty pharmacies (HSSPs). Health systems that have included the specialty pharmacy as part of the patient care team set themselves apart as they provide coordinated care that will become essential as value based contracting becomes a reality. HSSPs rely on clinical coordination with providers, pharmacists and patients resulting in a more comprehensive approach to a patient. While health systems have much to gain from building specialty pharmacies, understanding the challenges and how to overcome them is paramount in the highly competitive specialty pharmacy market.

To read the full article, as originally published in Becker's Hospital Review, click here.

1Quintiles IMS & AmerisourceBergen Internal Estimates
2Adam J. Fein, PHD, The 2017-18 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors, October 2017, accessed January 2018 at
3EMD Serono, 13th Edition EMD Serono Specialty Digest 2017, May 2017, accessed January 2018 at